DocMorris shareholders back board, reaffirm digital health strategy and 2026 break-even goal

DocMorris ( (CH:DOCM) ) has provided an update.

DocMorris shareholders backed the board’s leadership and strategy at the 2026 General Meeting in Zurich, rejecting proposals from minority shareholder CEPD N.V. for additional board seats and the chairmanship. The meeting re-elected three existing directors, appointed three new independent members, confirmed Walter Oberhänsli as chairman and approved the board’s slate for the Compensation and Nomination Committee.

Management framed the strong vote as an endorsement of DocMorris’s strategic direction and operational progress, while signaling openness to further dialogue with the largest shareholder about board representation. The company reiterated its plan to reach EBITDA break-even in 2026, highlighting 10.7 percent first-quarter sales growth and accelerated business momentum in the second quarter, suggesting continued confidence in its digital health growth trajectory.

The most recent analyst rating on (CH:DOCM) stock is a Buy with a CHF9.50 price target. To see the full list of analyst forecasts on DocMorris stock, see the CH:DOCM Stock Forecast page.

More about DocMorris

DocMorris AG is a Swiss-listed digital health company operating leading online pharmacy, telemedicine and health-product marketplaces across Germany and several European countries. The group runs a highly automated logistics hub in the Netherlands and TeleClinic, Germany’s largest telemedicine platform, serving over 12 million active customers and generating CHF 1,186 million in external sales in 2025.

Average Trading Volume: 279,765

Technical Sentiment Signal: Sell

Current Market Cap: CHF338.7M

See more insights into DOCM stock on TipRanks’ Stock Analysis page.